id	等位基因	注释文本
1055	*36	The CYP2D636 allele has been assigned as a no function allele by CPIC. Patients carrying the 36 allele in combination with a decreased, normal or no function allele may have decreased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the 36 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the 36 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.
1054	*10	The CYP2D610 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the 10 allele in combination with a decreased or no function allele may have decreased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the 10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the 10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.
1053	*5	The CYP2D65 allele has been assigned as a no function allele by CPIC. Patients carrying the 5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the 5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the 5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.
1052	*2	The CYP2D62 allele is assigned as a normal function allele by CPIC. Patients carrying the 2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of propafenone as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of propafenone as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of propafenone as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.
1051	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the 1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of propafenone as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of propafenone as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of propafenone as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.

id	证据的ID	总结
3934	1451330400	CYP2D6 10/10 is associated with increased concentrations of propafenone in people with Arrhythmias, Cardiac as compared to CYP2D6 1/1.
3933	1451294540	CYP2D6 1/5 + 2/36 + 5/10 + 5/5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of propafenone in people with Tachycardia as compared to CYP2D6 1/1 + 1/2 + 2/2 + 1/10 + 2/10 + 10/10 (assigned as intermediate metabolizer and normal metabolizer phenotype) .
3932	1450417472	CYP2D6 10/10 is associated with decreased metabolism of propafenone in healthy individuals as compared to CYP2D6 1/10 + 1/1.
3931	PA166104962	Annotation of DPWG Guideline for propafenone and CYP2D6

id	类型	评论
828	Note	Checked
827	Update	Added DPWG guideline and PMID 33203295 to evidence. Added 2, 5 and *36 alleles and rewrote phenotype descriptions to fit LOE 1A template. Independent curator check required before approval.
826	Update	CA score added as part of scoring system release. LOE may have automatically changed based on new score but may be subject to further changes upon curator review.
825	Update	Split VA 1183620540 into one VA on PK and one on efficacy. This CA is now solely on PK. Rewrote phenotype descriptions to be on alleles rather than diplotypes.
824	Update	Updated OMB race to appropriate biogeographical group

最新招商产品更多>>